Neurona Therapeutics has gained $102m to support the advancement of its investigational cell therapy, NRTX-1001, into Phase III testing for drug-resistant mesial temporal lobe epilepsy (MTLE).

We describe two brain-damaged subjects (P.C.O. and ... of color knowledge would seem to require the integrity of mesial temporal regions of the left hemisphere. Subjects P.C.O. and S.L.A. were ...

for drug-resistant mesial temporal lobe epilepsy (MTLE), which is among the most common types of epilepsy. In an ongoing multicenter, open-label Phase 1/2 trial in adults with drug-resistant MTLE ...

The asset, dubbed NRTX-1001, is currently being tested in an open-label phase 1/2 trial among patients with drug-resistant mesial temporal lobe epilepsy (MTLE), plus another phase 1/2 study for ...